Profile ng asset
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant ba…
Pinakabago muna.
Lakewood-Amedex Magpapakita ng Nu-3 sa ThinkEquity at IDWeek noong Oktubre 2026
Lakewood-Amedex doses first patient in Phase 2a trial of Nu-3 for infected diabetic foot ulcers
Lakewood-Amedex (LABT) Natanggap ang Pag-apruba ng IRB upang Simulan ang Phase 2a Trial ng Nu-3 sa Infected Diabetic Foot Ulcers
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05276401 | Phase 2 | Itinigil | May 18, 2022 | 3 | 5 sa 5 site ay nasa United States |
| NCT07565506 | Phase 2 | Nagre-recruit | Ene 1, 2027 | 24 | 6 sa 6 site ay nasa United States |
| NCT06020235 | Phase 2 | Hindi pa nagre-recruit | Hun 1, 2026 | 60 | |
| NCT02737722 | Phase 1/2 | Tapos na | Ago 1, 2017 | 31 | 3 sa 3 site ay nasa United States |
Iba pang gamot at kandidato ng parehong kumpanya na sinusubaybayan sa sektor na ito.